Susan E. Bates, MD, Internal Medicine ...

Dr. Susan E. Bates

Claim this profile

James J Peters VA Medical Center

Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
9 reported clinical trials
20 drugs studied

Area of expertise

1

Lung Cancer

Susan E. Bates has run 5 trials for Lung Cancer. Some of their research focus areas include:

Stage II
Stage I
Stage III
2

Non-Small Cell Lung Cancer

Susan E. Bates has run 5 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:

Stage IV
Stage III
Stage I

Affiliated Hospitals

Image of trial facility.

James J Peters VA Medical Center

Image of trial facility.

Columbia University Medical Center

Clinical Trials Susan E. Bates is currently running

Image of trial facility.

Treatment Timing

for Non-Small Cell Lung Cancer

This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed by surgery (resectable). The usual approach for patients with resectable NSCLC is chemotherapy and/or immunotherapy before surgery, after surgery, or both before and after surgery. This study is being done to find out which approach is better at treating patients with lung cancer. Treatment will be administered according to the current standard of care at the time of enrollment. Chemotherapy options may include cisplatin, carboplatin, pemetrexed, gemcitabine, docetaxel, and vinorelbine at standard doses according to the treating physician. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make deoxyribonucleic acid (DNA) and may kill tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Other chemotherapy drugs, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading . Immunotherapy with monoclonal antibodies, such as nivolumab, pembrolizumab, and atezolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with chemotherapy and immunotherapy prior to surgery and continuing treatment after surgery may be a more effective treatment option than adjuvant therapy alone in patients with stage II-IIIB resectable NSCLC.

Recruiting

2 awards

Phase 3

4 criteria

Image of trial facility.

Targeted Therapy Screening

for Lung Cancer

This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes non-match sub-studies which will include all screened patients not eligible for any of the biomarker-driven sub-studies.

Recruiting

1 award

Phase 2 & 3

13 criteria

More about Susan E. Bates

Clinical Trial Related

5 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 3 Active Clinical Trials

Treatments Susan E. Bates has experience with

  • Gemcitabine
  • Pembrolizumab
  • Pemetrexed
  • Nab-paclitaxel
  • Cisplatin
  • Gemcitabine Hydrochloride

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Susan E. Bates specialize in?

Is Susan E. Bates currently recruiting for clinical trials?

Are there any treatments that Susan E. Bates has studied deeply?

What is the best way to schedule an appointment with Susan E. Bates?

What is the office address of Susan E. Bates?

Is there any support for travel costs?

Unbiased Results

We believe in providing patients with all the options.

Your Data Stays Your Data

We only share your information with the clinical trials you're trying to access.

Verified Trials Only

All of our trials are run by licensed doctors, researchers, and healthcare companies.

Terms of Service·Privacy Policy·Cookies·Security